No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AMRX Amneal Pharmaceuticals
- 5.870
- -0.030-0.51%
Close Apr 26 16:00 ET
- 5.740
- -0.130-2.21%
Post 16:23 ET
1.81BMarket Cap-12229P/E (TTM)
5.975High5.840Low959.06KVolume5.900Open5.900Pre Close5.66MTurnover0.78%Turnover RatioLossP/E (Static)308.55MShares6.46052wk High91.72P/B718.13MFloat Cap1.74052wk Low--Dividend TTM122.34MShs Float24.480Historical High--Div YieldTTM2.29%Amplitude1.240Historical Low5.904Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
EDIT, CLNE and NIU Are Among After Hour Movers
Analysts Conflicted on These Healthcare Names: Amneal Pharmaceuticals (AMRX) and Community Health (CYH)
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise
Amneal Pharmaceuticals (AMRX) rallied Wednesday after the US Food and Drug Administration approved its generic version of the nasal spray used to treat opioid overdose. Amneal's Naloxone HCI nasal spr
FDA Approves Amneal's Generic Version of OTC Narcan
Express News | Amneal Pharmaceuticals Shares Are Trading Higher After the Company Announced FDA Approval of OTC Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opiod Overdose
Express News | Amneal Announces FDA Approval Of Over-The-Counter Naloxone Hydrochloride Nasal Spray For Emergency Treatment Of Opioid Overdose
Comments
Update
$Amneal Pharmaceuticals(AMRX.US$ Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
News
$Amneal Pharmaceuticals(AMRX.US$ Amneal Launches PEMRYDI RTU, The First Ready-To-Use Version Of Important Oncology Injectable Medicine
Benzinga· 2 mins ago
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration
Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forward – this is the first of 2024
Benzinga· 2 mins ago
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration
Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forward – this is the first of 2024
Update
$Amneal Pharmaceuticals(AMRX.US$ Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
1
$Amneal Pharmaceuticals(AMRX.US$
Wait for institutions to offer guidance before taking out gains !
Wait for institutions to offer guidance before taking out gains !
Do prayers Don’t FOMO
$Amneal Pharmaceuticals(AMRX.US$
DONT PaNICK
short sellers need to exit their position to cover, HOLD the GAIN(S)
DONT PaNICK
short sellers need to exit their position to cover, HOLD the GAIN(S)
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg